The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia
β Scribed by Carsten Stephan; Michael Lein; Klaus Jung; Dietmar Schnorr; Stefan A. Loening
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 102 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite Β΄, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many.
RESULTS.
The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patients with BPH, and 1.4 mg/L and 23.6% in the control group. Patients with PCa had a significantly lower proportion of f-PSA than BPH patients and healthy men. There was no correlation of f-PSA% to TNM stage or tumor grade. In PCa patients a significant positive correlation (correlation coefficient [r] Γ 0.51, P Γ΅ 0.001) was found between f-PSA% and prostate volume, whereas there was no significant correlation in BPH patients (r Γ 00.27, P ΓΊ 0.05). There was a significant difference in f-PSA% between PCa and BPH patients with prostate volumes smaller than 40 cm 3 (9.0% vs. 21.6%, P Γ΅ 0.01) but not between patients in these 2 groups with prostate volumes exceeding 40 cm 3 (15.1% vs. 18.2%, P Γ 0.11).
CONCLUSIONS.
Determining the ratio of f-PSA to t-PSA to discriminate between PCa and BPH patients yields significant results only in men with a prostate volume of less than 40 cm 3 . Cancer 1997; 79:104-9.
π SIMILAR VOLUMES
The ratio of free prostate-specific antigen (f-PSA) to total PSA (t-PSA) in serum, calculated as percent free PSA (f-PSA%), is lower in patients with prostate carcinoma (PCa) than in patients with benign prostate hyperplasia (BPH). This parameter facilitates discrimination between the 2 groups of pa
## BACKGROUND. To improve the clinical usefulness of prostate specific antigen (PSA),
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
Urinary excretion of nonesterified (NEC) and total cholesterol (TC) has been investigated in 79 patients with prostatic adenoma (BPH) and 48 patients with carcinoma of the prostate. Normal range of NEC was determined in 62 healthy individuals and was found to be 0.26-2.2 mg/24 hours (2 SD) with a me
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru